ACTMonitor®+  Liquid Biopsy for Cancer Monitoring


| ACTMonitor®+ Liquid Biopsy to Monitor Tumor Burden and Drug Resistance ACTMonitor® + uses circulating tumor DNA (ctDNA) to detection of cancer recurrence and drug resistance. ctDNA consists of fragments of DNA released from necrotic or apoptotic tumor cells into the bloodstream, which carries the important genetic information of cancer patients, and changes dramatically before changes can be observed by protein markers and in radioimages. Therefore, ctDNA provides a solid basis for molecular diagnostic tests. Monitoring ctDNA can detect the occurrence of variants that would lead to drug sensitivity or resistance, providing an assessment on treatment responses and early detection for cancer recurrence. | Key Features: - Repeated analyses of liquid biopsies over time enable long term disease monitoring - Provides real-time and comprehensive tumor mutation analyses - Monitors treatment outcome and provides information on the occurrence of mutations that leads to drug resistance - Applicable for different types of solid tumors - Providing a testing report in 10 working days.
Visit ID (prod)
ACT Genomics Co. Ltd.(Looking for distributors) Company IntroACT Genomics is a leading cancer genomic testing provider started in Taiwan in 2014. Now, we have grown and expanded into Japan, Singapore, Hong Kong, and the Southeast Asia region.With cutting-edge next-generation sequencing (NGS), proprietary bioinformatics analysis, and combined expertise in tumor biology, cancer genomics, bioinformatics, and artificial intelligence, our genomic tests provide treatment suggestions based on the tumor's genomic markup. With our tests, the doctors can formulate a personalized treatment plan to achieve a better outcome for their cancer patients.Our NGS-based TestsACTOnco® +: Tumor tissue-based (FFPE)Provides comprehensive genetic information on the potential therapeutic response (i.e. to targeted therapy, chemotherapy, immunotherapy)Incorporates pathway-based analysis for a holistic overview & therapeutic recommendations440 cancer-related genes (including 13 fusion genes)All types of solid tumors (lung, breast, colorectal, prostate, TNBC, pancreatic, ovarian, CCA, liver, glioblastoma, rare cancer, and other solid tumors)ACTHRD™:  Tumor tissue-based (FFPE)Determines BRCA 1/2, LOH, and HRD status for PARP inhibitor treatment24 HRR-related genes (including BRCA1/2)Ovarian cancer and HRD-/HRR-related cancer typesACTDrug® +:  Tumor tissue-based (FFPE)Focuses on clinically recommended biomarkers for targeted therapies40 actionable genes (including 13 fusion genes)Common cancer types: lung cancer, gastric cancer, colon cancer, prostate cancer, etc.ACTLung™: Tumor tissue-based (FFPE)Focuses on biomarkers associated with lung cancer for targeted therapy13 lung-cancer-related genes (including 8 fusion genes)Lung cancerACTMonitor® +:  Blood-based (ctDNA)Monitors disease burden and treatment response/resistance50 cancer-related genesSolid tumors (Pan-cancer)